IL264964A - - Google Patents
Info
- Publication number
- IL264964A IL264964A IL26496419A IL26496419A IL264964A IL 264964 A IL264964 A IL 264964A IL 26496419 A IL26496419 A IL 26496419A IL 26496419 A IL26496419 A IL 26496419A IL 264964 A IL264964 A IL 264964A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7019—Ischaemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610705624.2A CN106967172B (zh) | 2016-08-23 | 2016-08-23 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| PCT/CN2017/098466 WO2018036473A1 (zh) | 2016-08-23 | 2017-08-22 | 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL264964A true IL264964A (https=) | 2019-04-30 |
| IL264964B1 IL264964B1 (en) | 2023-06-01 |
| IL264964B2 IL264964B2 (en) | 2023-10-01 |
Family
ID=59334390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264964A IL264964B2 (en) | 2016-08-23 | 2017-08-22 | Anti-CTLA4 and anti-PD1 bifunctional antibody, pharmaceutical preparation thereof and use thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11578128B2 (https=) |
| EP (1) | EP3511346A4 (https=) |
| JP (2) | JP7425604B2 (https=) |
| KR (1) | KR102503084B1 (https=) |
| CN (1) | CN106967172B (https=) |
| AU (1) | AU2017317124B2 (https=) |
| BR (1) | BR112019003695A2 (https=) |
| CA (1) | CA3034850A1 (https=) |
| EA (1) | EA201990571A1 (https=) |
| IL (1) | IL264964B2 (https=) |
| MX (1) | MX2019002254A (https=) |
| NZ (2) | NZ791623A (https=) |
| SG (1) | SG11201901583WA (https=) |
| WO (1) | WO2018036473A1 (https=) |
| ZA (1) | ZA201901782B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN106977602B (zh) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN108866635B (zh) * | 2017-05-09 | 2021-11-26 | 安升（上海）医药科技有限公司 | 多特异性蛋白药物及其文库、以及制备方法和应用 |
| CN110799546B (zh) * | 2017-09-01 | 2023-01-24 | 四川科伦博泰生物医药股份有限公司 | 重组双特异性抗体 |
| SG11202003237QA (en) * | 2017-11-02 | 2020-05-28 | Systimmune Inc | Bispecific antibodies and methods of making and using thereof |
| WO2019179421A1 (en) * | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/ctla-4 antibody molecules |
| CN110407942B (zh) * | 2018-04-27 | 2022-02-22 | 苏州康宁杰瑞生物科技有限公司 | 针对kn044的单域抗体 |
| CN112399973B (zh) * | 2018-06-05 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| CN110684113A (zh) * | 2018-07-06 | 2020-01-14 | 复旦大学 | 一种抗PD-1抗原和抗c-Met抗原的双特异性抗体及其构建方法 |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆（苏州）医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| WO2020057610A1 (en) * | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
| WO2020057611A1 (en) * | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific ctla-4/pd-1 polypeptide complexes |
| CN111763261B (zh) * | 2019-04-02 | 2022-08-09 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| CN112175087B (zh) * | 2019-07-02 | 2022-05-13 | 深圳市迈加瑞生物技术有限公司 | 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途 |
| CN112513097B (zh) * | 2019-07-11 | 2021-10-29 | 武汉友芝友生物制药有限公司 | 四价对称双特异性抗体 |
| WO2021023117A1 (zh) | 2019-08-02 | 2021-02-11 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
| BR112022002028A2 (pt) | 2019-08-02 | 2022-04-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anticorpo anti-pd-1 e uso farmacêutico do mesmo |
| CN112442126B (zh) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
| CN110563845A (zh) * | 2019-09-12 | 2019-12-13 | 滨州医学院 | 抗igsf9抗体、药物组合物及其应用 |
| PH12022551278A1 (en) | 2019-11-25 | 2023-11-20 | Akeso Biopharma Inc | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof |
| US12565531B2 (en) | 2019-12-04 | 2026-03-03 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Bispecific fusion protein for tumor treatment |
| CA3176321A1 (en) * | 2020-04-22 | 2021-10-28 | Peng Zhang | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| WO2021213523A1 (zh) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 |
| BR112022022020A2 (pt) * | 2020-04-29 | 2023-01-31 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Proteína bifuncional contra pd-1 e tgf-ss |
| CN113577255B (zh) * | 2020-04-30 | 2023-09-08 | 中国科学院上海药物研究所 | 肿瘤纳米疫苗、其制备方法及用途 |
| CN113754767A (zh) * | 2020-06-03 | 2021-12-07 | 上海恒润达生生物科技股份有限公司 | 抗人pd-1抗体及其用途 |
| TW202220691A (zh) * | 2020-07-27 | 2022-06-01 | 美商宏觀基因股份有限公司 | 用於使用ＰＤ—１ｘＣＴＬＡ—４雙特異性分子的方法 |
| CN111944760A (zh) * | 2020-08-14 | 2020-11-17 | 广东先康达生物科技有限公司 | 一种分泌双特异性抗体的免疫细胞及其应用 |
| CN112079926A (zh) * | 2020-09-17 | 2020-12-15 | 北京华大蛋白质研发中心有限公司 | 抗人ctla4单克隆抗体及其应用 |
| CN120590533A (zh) * | 2020-10-23 | 2025-09-05 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| EP4190819A4 (en) | 2021-03-12 | 2024-08-14 | Akeso Biopharma, Inc. | PHARMACEUTICAL COMBINATION CONTAINING BISPECIFIC ANTI-PD-1-ANTI-VEGFA ANTIBODY, AND USE THEREOF |
| CN115073588B (zh) * | 2021-03-12 | 2024-06-18 | 中山康方生物医药有限公司 | 提高含有免疫球蛋白Fc片段的药物的安全性的方法 |
| EP4324854A4 (en) | 2021-04-14 | 2025-04-23 | Akeso Pharmaceuticals, Inc. | USE OF ANTIBODIES IN ANTITUMOR TREATMENT |
| CN113501879B (zh) * | 2021-06-30 | 2022-09-06 | 拜盖特生物科技(上海)有限公司 | 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法 |
| IL310217A (en) * | 2021-07-23 | 2024-03-01 | Akeso Biopharma Inc | Pharmaceutical composition and use |
| JP2024536881A (ja) | 2021-09-29 | 2024-10-08 | 中山康方生物医▲藥▼有限公司 | 抗ｌａｇ３抗体、医薬組成物、及び使用 |
| CN118541390A (zh) * | 2022-01-30 | 2024-08-23 | 百奥赛图(北京)医药科技股份有限公司 | 抗ctla4/ox40双特异性抗体及其用途 |
| WO2023160647A1 (zh) | 2022-02-24 | 2023-08-31 | 康方药业有限公司 | 包含抗ctla4-抗pd-1双特异性抗体和西奥罗尼的药物组合 |
| CN117679505A (zh) | 2022-09-09 | 2024-03-12 | 中山康方生物医药有限公司 | 药物组合及用途 |
| CA3208447A1 (en) * | 2022-09-09 | 2024-03-09 | Akeso Biopharma, Inc. | Therapeutic combination and use thereof |
| CN116396392B (zh) * | 2023-01-17 | 2023-10-27 | 珠海重链生物科技有限公司 | 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用 |
| JP2026507907A (ja) | 2023-03-07 | 2026-03-06 | アケソ・ファーマ・カンパニー，リミテッド | 抗ｃｔｌａ４抗ｐｄ－１二重特異性抗体を含有する医薬組成物とその使用 |
| CN118767127A (zh) | 2023-04-10 | 2024-10-15 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体的医药用途 |
| WO2025157267A1 (zh) * | 2024-01-25 | 2025-07-31 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体的医药用途 |
| WO2025201450A1 (zh) * | 2024-03-27 | 2025-10-02 | 康方汇科(上海)生物有限公司 | 药物组合及用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| CN106432474A (zh) * | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| MY175472A (en) | 2013-09-27 | 2020-06-29 | Genentech Inc | Anti-pdl1 antibody formulations |
| SG10201804945WA (en) * | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| EP3089758B1 (en) * | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN104974253A (zh) | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| CN104987421A (zh) | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| CN105175544B (zh) | 2015-10-20 | 2021-04-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
| CN105175545B (zh) | 2015-10-20 | 2019-01-25 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
| IL260021B (en) * | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| CN105754990A (zh) | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| WO2021023117A1 (zh) | 2019-08-02 | 2021-02-11 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
-
2016
- 2016-08-23 CN CN201610705624.2A patent/CN106967172B/zh active Active
-
2017
- 2017-08-22 IL IL264964A patent/IL264964B2/en unknown
- 2017-08-22 AU AU2017317124A patent/AU2017317124B2/en active Active
- 2017-08-22 EA EA201990571A patent/EA201990571A1/ru unknown
- 2017-08-22 MX MX2019002254A patent/MX2019002254A/es unknown
- 2017-08-22 KR KR1020197008463A patent/KR102503084B1/ko active Active
- 2017-08-22 JP JP2019531513A patent/JP7425604B2/ja active Active
- 2017-08-22 EP EP17842896.7A patent/EP3511346A4/en active Pending
- 2017-08-22 NZ NZ791623A patent/NZ791623A/en unknown
- 2017-08-22 NZ NZ751904A patent/NZ751904A/en unknown
- 2017-08-22 CA CA3034850A patent/CA3034850A1/en active Pending
- 2017-08-22 US US16/327,076 patent/US11578128B2/en active Active
- 2017-08-22 BR BR112019003695-4A patent/BR112019003695A2/pt unknown
- 2017-08-22 WO PCT/CN2017/098466 patent/WO2018036473A1/zh not_active Ceased
- 2017-08-22 SG SG11201901583WA patent/SG11201901583WA/en unknown
-
2019
- 2019-03-22 ZA ZA2019/01782A patent/ZA201901782B/en unknown
-
2022
- 2022-06-01 JP JP2022089567A patent/JP2022130393A/ja active Pending
- 2022-12-16 US US18/067,669 patent/US12479919B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106967172A (zh) | 2017-07-21 |
| KR20190052677A (ko) | 2019-05-16 |
| WO2018036473A1 (zh) | 2018-03-01 |
| NZ791623A (en) | 2025-12-19 |
| US12479919B2 (en) | 2025-11-25 |
| KR102503084B1 (ko) | 2023-02-24 |
| US11578128B2 (en) | 2023-02-14 |
| EP3511346A1 (en) | 2019-07-17 |
| EA201990571A1 (ru) | 2019-08-30 |
| NZ751904A (en) | 2023-01-27 |
| IL264964B2 (en) | 2023-10-01 |
| US20240010728A1 (en) | 2024-01-11 |
| IL264964B1 (en) | 2023-06-01 |
| AU2017317124B2 (en) | 2024-09-26 |
| CN106967172B (zh) | 2019-01-08 |
| ZA201901782B (en) | 2026-03-25 |
| AU2017317124A1 (en) | 2019-04-11 |
| JP2019533475A (ja) | 2019-11-21 |
| JP7425604B2 (ja) | 2024-01-31 |
| EP3511346A4 (en) | 2020-04-29 |
| SG11201901583WA (en) | 2019-03-28 |
| US20190185569A1 (en) | 2019-06-20 |
| NZ791621A (en) | 2025-10-31 |
| MX2019002254A (es) | 2019-11-28 |
| CA3034850A1 (en) | 2018-03-01 |
| BR112019003695A2 (pt) | 2019-06-04 |
| JP2022130393A (ja) | 2022-09-06 |